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 Abstract   
The epidermal growth factor receptor (EGFR), a long-standing drug development target, is also a 
desirable target for imaging. Sixteen dialkoxyquinazoline analogs, suitable for labeling with positron-
emitting isotopes, have been synthesized and evaluated in a battery of in vitro assays to ascertain their 
chemical and biological properties. These characteristics provided the basis for the adoption of a 
selection schema to identify lead molecules for labeling and in vivo evaluation. A new EGFR tyrosine 
kinase radiometric binding assay revealed that all of the compounds possessed suitable affinity (IC50 = 
0.4 - 51 nM) for the EGFR tyrosine kinase. All of the analogs inhibited ligand-induced EGFR tyrosine 
phosphorylation (IC50 = 0.8 - 20 nM). The HPLC-estimated octanol/ water partition coefficients ranged 
from 2.0-5.5. Four compounds, 4-(2´-fluoroanilino)- and 4-(3´-fluoroanilino)-6,7-diethoxyquinazoline 
as well as 4-(3´-chloroanilino)- and 4-(3´-bromoanilino)-6,7-dimethoxyquinazoline, possess the best 
combination of characteristics that warrant radioisotope labeling and further evaluation in tumor-bearing 
mice. 
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 Introduction 
Protein tyrosine kinases (PTKs), enzymes that phosphorylate tyrosine residues on functional 
proteins, are common mediators of signals that regulate many cellular processes. PTKs can be divided 
into two subgroups based on their structural characteristics, nonreceptor cytoplasmic PTKs and receptor 
tyrosine kinases (RTKs).1 To date at least 20 families of receptor tyrosine kinases that share structural, 
most notably an intrinsic tyrosine kinase domain, and functional similarities have been classified.2,3 The 
epidermal growth factor receptor (EGFR) was one of the first oncogenes and receptor tyrosine kinases 
to be discovered.4,5 EGFR belongs to the ErbB family of receptors, which also includes ErbB2 
(HER2/Neu), ErbB3 and ErbB4. These receptors are overexpressed in a variety of tumors.  
EGFR tyrosine kinase phosphorylation is stimulated by epidermal growth factor (EGF) or 
transforming growth factor α (TGFα) binding to the extracellular ligand binding domain of the EGFR 
and subsequent receptor dimerization. Signal transduction initiated by these events regulates cellular 
proliferation, differentiation, motility, adhesion and apoptosis. These signaling processes play an 
important role in normal epithelial and stromal cell morphology; moreover, overexpression or aberrant 
signaling from EGFR and the other ErbB receptor family members has been shown to be a key 
determinant in tumor growth and proliferation.6,7 
Overexpression of EGFR has been found in head and neck tumors, gliomas, non-small cell lung 
carcinoma and tumors of the breast, ovaries, cervix, esophagus, bladder, prostate, and kidney.7 There is 
extensive literature on the clinical significance of increased EGFR expression and signaling in tumors 
and the relationship to other prognostic factors.8,9 In a majority of tumors poor survival rates correlate 
with EGFR overexpression. For example, EGFR overexpression has been detected in nearly 45 percent 
of the breast tumors studied10 and receptor overexpression is inversely correlated with patient survival.9 
EGFR overexpression is also inversely correlated with estrogen receptor status, consistent with the 
failure of EGFR positive patients to respond to hormonal therapies.11,12 The relevance of EGFR 
expression in tumors to prognostic outcome supports the years of investment towards finding an EGFR-
targeted therapeutic13-18 and the need for a diagnostic imaging agent. Development of an imaging agent 
might also be a valuable tool in the search for and the characterization of EGFR-targeted therapeutics.  
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 Two potential targets for EGFR-based probes are the extracellular domain or the intracellular 
tyrosine kinase domain. Radioactive probes that bind to the extracellular domain of EGFR have been 
generated. EGF, the 53 amino acid, 6 kDa, natural ligand, binds to the EGFR with a Kd of 0.1-1.0 nM 19 
and has been labeled directly with iodine-123, iodine-125 and iodine-131. In vitro studies using 
[131I]EGF demonstrated its cytotoxic potential.20 123I-EGF has been used to image cervical cancer in 
humans.21 In spite of its ability to localize in EGFR rich tissue, radioiodinated EGF rapidly degrades in 
vivo releasing radioiodine thereby reducing the lifetime of the label in the tumor.22 Iodinated dextran-
EGF conjugates increase retention of the iodine by tumor cells but at the cost of higher molecular 
weight that affects tracer distribution.20 EGF has been labeled with technetium-99m using a MAG3 or 2-
iminothiolane chelate and was found to accumulate in tumor xenografts with more rapid clearance than 
labeled monoclonal antibodies (Mabs).23-25 Bifunctional chelation of indium-111 to EGF using 
diethylenetriaminepentaacetic acid (DTPA) has been shown to have cytotoxic effects in vitro and is 
being investigated as a potential radiotherapeutic agent.26,27 The imaging potential of 111In-EGF was 
found to be inferior to a labeled anti-EGFR antibody, 111In-DTPA-MAb 528 in tumor bearing rats.28 
Several MAbs against EGFR have been developed as anti-tumor agents. The radioiodinated 
Mab, EGFR1, with high affinity for the EGFR has demonstrated good uptake in MCF-7 tumors grown 
in nude athymic mice29 and good localization in human brain gliomas.30 Likewise, the indium-111 
labeled C225 Mab has been tested in patients with squamous cell lung carcinoma.31 A direct-labeled 
technetium-99m anti-EGFR antibody, ior egfr/r3, has demonstrated imaging sensitivity (84%), 
specificity (100%) and accuracy (86.5%) in human epithelial tumors.32 However, MAbs labeled with 
short-lived PET isotopes, in general, have demonstrated limited targeting success in large part due to 
pharmacokinetic constraints related mostly to their size.  
To date no small organic molecules with affinity for the extracellular domain of the EGFR have 
been identified; however, a number of small molecules have been shown to be potent (nM to pM) 
inhibitors of the intracellular EGFR tyrosine kinase at the ATP binding site. A sampling of the different 
compound classes that inhibit EGFR phosphorylation is shown in Figure 1. The dialkoxy-
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 anilinoquinazolines (Figure 1) were chosen as the lead compounds in the present study based on the 
strong structure-activity data.33-35  
The development of imaging agents based on the small molecule EGFR inhibitors has been a 
recent area of active research. A number of radiolabeled anilinoquinazoline analogs have been reported. 
The compounds incorporate labeled substituents on the A or C rings (see Figure 1) of the anilino- or 
benzylamino- quinazoline. The C ring substituted analogs include 4-(3'-[125I]iodoanilino36,37, 4-(3'-
[18F]fluoro-5'-trifluoromethylanilino)-38, 4-(3',4'-dichloro-6'-[18F]fluoroanilino)-38, and 4-(3'-chloro-4'-
[18F]fluoroanilino)-39. The 7-[18F]fluoroethoxy-40 and the 6- or 7-[11C]methoxy- 40,41 constitute the A 
ring labeled analogs. Preliminary in vitro studies with the 3'-[125I]iodo analog demonstrated receptor 
mediated uptake in cells containing high EGFR titer.37 A study of the carbon-11 methoxy derivative 
demonstrated some uptake in human neuroblastoma xenografts in mice42,43; however, the 20 min half-
life of the carbon-11 may not allow adequate time for the development of good signal relative to 
background. Bonasera and colleagues evaluated five fluorine-18 labeled compounds.38 They studied the 
4-(4'-[18F]fluoroanilino)-dimethoxyquinazoline and the 4-(3',4'-dichloro-6'-[18F]fluoroanilino)-
dimethoxyquinazoline in tumor-bearing mice. These tracers did not accumulate in the tumors nor was 
receptor-mediated uptake, based on blocking studies, observed for the latter probe. Low receptor 
affinity, high non-specific binding and probe metabolism may have contributed to the inability of these 
compounds to accumulate in tumor cells that overexpress EGFR. 
Successful development of an imaging probe targeting a new biomarker, in this case EGFR, 
requires an adequate screening strategy for the selection of ligands to be carried forward for labeling 
and, ultimately, in vivo studies. It is neither economically nor logistically feasible to label and evaluate 
every compound in animal models. Likewise, navigating the structure activity relationships in the 
medicinal chemistry literature can be challenging with respect to choosing an appropriate imaging lead 
compound. For example, the fact that a small molecule is a potent EGFR inhibitor does not necessarily 
guarantee that it will possess desirable EGFR imaging characteristics such as high receptor affinity, high 
receptor selectivity, low non-specific binding, rapid clearance and suitable metabolism.  
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 In the current study, a small series of dialkoxyquinazoline EGFR inhibitors suitable for labeling 
with fluorine-18 (110 min half-life positron-emitter) or carbon-11 (20 min half-life positron-emitter) has 
been synthesized. Appropriate assays have been developed to determine both functional and imaging 
characteristics, including a new radiometric binding assay to measure the affinity of the inhibitors for 
the enzyme. These studies provide the basis needed for the selection of ligands to be labeled and further 
evaluated as potential imaging agents for the non-invasive determination of EGF receptor density. 
 
Results 
 
Chemistry. 
A small library of anilino- and benzyl-dialkoxyquinazoline compounds 10-17 were prepared by 
coupling 4-chloro-dialkoxyquinazoline 8 or 9 with the appropriate substituted aniline or benzylamine 
(Scheme 3).  The 4-chloro-6,7-dimethoxyquinazoline was synthesized as previously reported from the 
4,5-dimethoxyanthranilic acid 5.33 As the 4-(3´-bromoanilino)-6,7-diethoxyquinazoline was reported33 
to possess more potent biological activity than the corresponding 6,7-dimethoxy analog, we were 
interested in finding a convergent synthetic route suitable for the preparation of several diethoxy 
analogs. The previously reported two step conversion of the dimethoxy-bromoanilinoquinazoline 11c to 
the diethoxy analog 10c (Scheme 3), using a pyridinium hydrochloride melt to give the bishydroxy 
intermediate followed by O-alkylation with iodoethane, proceeded in a low 5.5% yield.33 This was 
inadequate for the preparation of a series of the diethoxy analogs. Thus, we produced the 4,5-
diethoxyanthranilic acid 4 by two methods (Scheme 1). Initially, a small amount of methyl 2-amino-4,5-
diethoxybenzoate 3 was commercially available from Aldrich Specialty Chemical.  The benzoate 3 was 
directly converted to 4 by saponification of the methyl ester.  Alternatively, when the commercial 
supply was depleted, 4,5-diethoxybenzoic acid 1 was nitrated to give 2 followed by reduction of the 
nitro group to form the desired amino-benzoic acid 4 in moderate overall yield. 
Preparation of the 4-chloroquinazolines followed a previously described procedure (Scheme 2).33 
Cyclization of the dialkoxyanthranilic acids, 4 or 5, with formamidine hydrochloride at 210˚C gave the 
corresponding dialkoxyquinazolinones, 6 or 7, in 55-65% yield. The quinazolinones were subsequently 
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 refluxed with oxalyl chloride in DMF and 1,2-dichloroethane to form the 4-chloro-dialkoxyquinazolines 
8 and 9 in good yield. 
A modified coupling procedure was employed for the production of the anilino- and benzylamino-
quinazolines (Scheme 3).  Anhydrous DMF was used as the reaction solvent instead of the previously 
reported isopropanol. The reaction was carried out at 80˚C with nearly quantitative conversion to the 
substituted aminoquinazoline hydrochloride (HCl) salt within 30 min to 1 h depending on the aniline 
substituents. The precipitated HCl salt was filtered from the DMF solution and was converted to the free 
base for semi-preparative normal phase HPLC purification.  The pure quinazolines were reconverted to 
the more stable HCl salt for the biological assays.  
Chemical and physical data for all of the compounds is presented in Table 1. All of the anilino- and 
benzyl- quinazoline analogs were analyzed by analytical reversed-phase HPLC and found to be greater 
than 99% pure. Elemental analysis of all of the dialkoxyquinazoline analogs in Table 1 agree with the 
calculated values to within ±0.4% 
Lipophilicity measurement. 
The lipophilicity of compounds can affect their tissue permeability properties that can impact their 
localization in target tissues. Lipophilicity may also affect binding to low affinity nonspecific sites that 
can compromise target tissue to background tissue ratios. The octanol/water partition coefficients of the 
quinazoline compounds were estimated by a reversed-phase HPLC method.44 This method has been 
previously used by us to determine lipophilicities of steroid ligands.45 The estimated Log Po/w values are 
reported in Table 1. The lipophilicities generally exhibited the expected trends with a couple of noted 
exceptions. The lipophilicity was greater for the diethoxy series relative to the corresponding dimethoxy 
analogs. Within the series 10a-d and 11a-d the lipophilicity increased with increasing size of the 
halogen from fluorine to iodine. Adding the trifluoromethyl moiety to 10a and 11a increased the 
lipophilicity by 1.7-1.8 log units. Interestingly, adding an extra methylene to produce the benzylamine 
did not significantly increase the compound lipophilicity (compare 14 and 16b, 15 and 17b). In contrast, 
the position of the fluorine on the aniline (C ring, Figure 1) ring did have a significant effect on the 
lipophilicity. The meta- and para- fluoroanilino analogs, 10a and 16b, had similar lipophilicities while 
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 the ortho- substituted analog, 16a, showed a 0.7 log unit decrease. This trend was similar for the 
dimethoxy analogs. 
Biological Activity. 
The sixteen quinazoline compounds were studied in a battery of in vitro assays to assess their 
biological properties and to develop a basis for screening these and future compounds for potential 
imaging agents. A radiometric binding assay was developed to determine the relative binding affinities 
of these compounds for the ATP binding site in the tyrosine kinase domain of the receptor. The ability 
of these molecules to inhibit EGFR tyrosine phosphorylation was probed. The specificity of a small 
subset of compounds was determined by assessing inhibition of ErbB2 and ErbB4 receptor 
phosphorylation. Finally, the ability of the ligand to inhibit cellular DNA synthesis, in cells dependent 
and not dependent on EGF for cell proliferation, was evaluated. This assay was performed in an effort to 
find a test that would be amenable to high throughput screening and whose results would potentially 
correlate with receptor binding and ultimately with the pharmacokinetic distribution of the tracer in vivo. 
Receptor binding is a key characteristic that these molecules must possess to be suitable imaging 
agents. A receptor binding assay using EGF receptors extracted from the A431 human carcinoma cell 
membranes was developed and used to study the relative binding affinity of these compounds to the 
tyrosine kinase domain. Iodine-125 labeled 11d (specific activity 583-596 Ci/mmol) was employed as 
the radioligand36 and non-specific binding was determined by adding 11c, the bromo- analog, to the 
assay. EGFR binding values, expressed as an IC50, are shown in Table 2. All of the compounds 
demonstrated high affinity for the receptor with IC50s ranging from 0.4 – 51 nM. In all cases the 
diethoxy analogs had relatively higher affinity for the receptor than the corresponding dimethoxy 
derivatives. Analogs 10b-10d and 11b-11d, the meta- chloro-, bromo- and iodo-anilino analogs, 
exhibited the highest relative affinities (nanomolar to subnanomolar) for the tyrosine kinase domain. 
Three fluoroanilino analogs, 10a, 12, and 16a displayed relative affinities slightly less than 10 nM, 
generally considered the upper limit for imaging agents46,47, while the remaining analogs had relative 
affinities greater than 16 nM.  
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 While receptor binding is absolutely necessary for localization of a potential imaging agent, the 
ability to inhibit receptor function, in this case ligand-induced receptor tyrosine autophosphorylation, 
may be uncoupled from ligand binding. A series of assays were designed to examine the correlation 
between receptor binding and inhibition of receptor phosphorylation or inhibition of EGF-dependent 
DNA synthesis. The inhibition of ligand-induced EGFR tyrosine autophosphorylation is reported in 
Table 2. All of the compounds were potent inhibitors of EGFR tyrosine phosphorylation (kinase 
activity) with the exception of the 4-(3´-fluoro-5´-trifluoromethylanilino)-6,7-diethoxyquinazoline 
analog 12. There was no correlation (r2 = 0.02) between binding affinity and inhibition of ligand-
induced EGFR tyrosine phosphorylation. Indeed, in contrast to the results of the receptor binding assay, 
in the EGFR tyrosine phosphorylation assays the diethoxy analogs were not consistently better 
inhibitors than the corresponding dimethoxy analogs. 
Specificity for the EGF receptor versus other receptor tyrosine kinases, especially ErbB2 and ErbB4, 
is another desirable imaging characteristic. Thus, a small set of compounds was evaluated for inhibition 
of ligand-induced ErbB2 and ErbB4 tyrosine phosphorylation (kinase activity). The specificity of the 
compounds tested for EGFR appears to be high (Table 2).  For the four compounds tested (10c, 10d, 
11c, and 14), the ErbB2 and ErbB4 tyrosine phosphorylation (kinase) IC50 values were at least one order 
of magnitude greater than the EGFR tyrosine phosphorylation (kinase) IC50 values. We do recognize 
that this is a comparison of phosphorylation inhibition rather than binding. 
The specificity of the molecules for EGFR was also determined by examining their effect on DNA 
synthesis by the EGF-dependent MCF-10A human mammary epithelial cell line and the EGF-
independent MCF-7 human mammary tumor cell line.  These cell lines were treated with various 
concentrations of several of the compounds and DNA synthesis was measured by assaying 3H-thymidine 
incorporation.  These data were used to calculate the DNA synthesis IC50 values for each compound in 
the two cell lines, shown in Table 3. The MCF7 DNA synthesis IC50 values for the compounds were at 
least one order of magnitude higher than the corresponding MCF10A DNA synthesis IC50 values.  
Because the DNA synthesis of MCF10A cells is EGF-dependent, these data suggest that the compounds 
inhibit MCF10A DNA synthesis by inhibiting the EGFR rather than some other target. 
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Discussion 
 There are four well-established criteria for the development of disease-specific radioprobes that 
would be sensitive to changes in binding site concentration.46,47 They are: i) identify a binding site 
whose concentration changes as a function of a specific disease; ii) design and produce a radioprobe that 
selectively targets the binding site; iii) evaluate sensitivity as a function of altered binding site 
concentration; and iv) evaluate sensitivity relative to the selected disease. The EGF receptor 
overexpression in various tumors satisfies the first criterion.  Identifying lead molecules to test as 
imaging probes and developing an underlying selection process to identify future candidate molecules, 
the subject of the present effort, begins to address the second criterion. 
 Designing and producing an enzyme- or receptor-binding radioprobe involves several steps, 
often an iterative process, intended to obtain a thorough understanding of the biochemical and 
physiological behavior of the probe to match against a set of desirable imaging characteristics.46,47 A 
receptor-binding radiotracer should meet the following criteria: i) high affinity for the desired enzyme or 
receptor, typically <10 nM; ii) appropriate lipophilicity (coupled to cell membrane or blood-brain 
barrier penetration, typically 1.5 – 3.0); iii) high selectivity for the enzyme or receptor (e.g. low affinity 
for receptors within the same family or similar proteins, typically >10:1); iv) suitable metabolic 
properties (labeled metabolites can alter the distribution profile of the probe); and v) rapid clearance 
from non-target tissues and the body (necessary for good target-to-background ratio, typically >3:1 and 
lower radiation dose to the subject). In vitro data for a series of dialkoxyquinazoline EGFR-targeted 
compounds have been gathered and used to select probes for labeling and in vivo evaluation. These data 
were used to establish a ligand selection process. The process is detailed in the context of the following 
discussion. 
The dialkoxyquinazolines (Figure 1) were chosen as the lead compounds in the present study 
based on the reported structure inhibition relationships.33-35 Fry and colleagues demonstrated that the 
quinazoline backbone and the 6,7-dimethoxy moieties were necessary for enhanced EGFR tyrosine 
kinase inhibition. The 6,7-diethoxy analog 10c  exhibited a four-fold lower inhibition IC50 value (6 pM 
 10 
 vs 25 pM) and halogen substitution at the 2´, 3´, 4´ and 5´ positions, even 3´, 4´ dibromination, of the 
anilino ring (“C” ring Figure 1) was well tolerated. The fluorobenzylamino analog was not previously 
studied but based on the radiochemical availability of this analog it was included here.48 The 
unsubstituted benzyl compound was evaluated as an inhibitor and found to have a 3 fold lower 
inhibition IC50 value (10 nM) compared to the corresponding unsubstituted anilino compound (29 
nM).33,35 The 3-fluoro-5-trifluoromethylaniline as well as 2-, 3- and 4- fluoroaniline can be synthesized 
with fluorine-18 so the corresponding non-radioactive analogs were added to the study.49 Inhibition data 
from the 4-(3’-trifluoromethylanilino)-6,7-dimethoxyquinazoline (inhibition IC50 = 0.24 nM) and the 3’-
fluoroanilino analog (inhibition IC50 = 3.8 nM) supported their inclusion.  
The preparation of the analogs for this study was straightforward. The 4-chloro- dimethoxy- or 
diethoxy-quinazoline intermediates were synthesized and coupled with the appropriate aniline or 
benzylamine to yield the desired anilino- or benzylamino-quinazolines in good yield. The approach 
outlined herein improved upon the chemistry previously described by Bridges et al.33 and provides a 
suitable starting point to generate libraries of anilino- or benzylamino- quinazolines with any dialkoxy 
or mixed alkoxy substituents in the 6 and 7 positions. 
 A receptor binding assay was developed to study the affinity of the compounds for the tyrosine 
kinase binding site and determine the correlation, if any, between binding and inhibition values. In vitro 
equilibrium binding assays provide a good means of segregating potential receptor-based imaging 
agents from those whose unfavorable kinetics (high binding potential, Bmax/Kd) might lead to flow 
mediated distribution.47 As all of the literature for the quinazolines and other classes of compounds 
targeting the EGFR tk reported inhibition constants, the following question was posed: Could these 
values be used as a primary determinant for potential imaging probes? All of the compounds possessed 
suitable affinity for the EGFR tk (IC50 range = 0.4 - 51 nM). Likewise, all of the compounds were nM 
inhibitors of ligand-induced EGFR tyrosine phosphorylation (IC50 range = 0.8 – 23.1 nM) in whole cells. 
Yet, there was a complete lack of correlation between the matched set of binding and phosphorylation 
data. Based on this small set of compounds the phosphorylation data may not be used to predict receptor 
affinity. This is likely due to the fact that inhibition of ligand-induced receptor phosphorylation is not 
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 only a function of receptor binding affinity, but is also a function of the ability to penetrate a cell and 
gain access to the receptor. Thus, the receptor binding assay along with a measure of cell penetration 
(inhibition of EGFR dependent DNA synthesis, see below) will be integral as an initial screen for 
tracers. Compounds 10a-d, 11b-d, 12 and 16a meet the generally accepted minimum affinity for 
receptor-based imaging agents, 10 nM. 
 A subsequent screen of selected lead compounds for the inhibition of ligand-induced tyrosine 
phosphorylation will identify those molecules that readily access the receptor.  For example, compound 
12 has a suitable affinity for EGFR in vitro but displays minimal inhibition of ligand-induced receptor 
tyrosine phosphorylation.  Thus, compound 12 probably possesses limited penetration of cells and/or 
limited EGFR access.  Therefore, compound 12 is likely to be of limited value as a potential EGFR-
specific tumor imaging agent. Compounds 10a-d, 11b-d, and 16a are potent inhibitors of EGFR 
phosphorylation. 
 In cases where facilitated transport is nonexistent cell membrane permeability is a direct function 
of the diffusion coefficient and compound lipophilicity. If the partition coefficient value is too low, the 
compound will not cross a cell membrane; if the value is too high, hydrophobic interactions with lipids 
and proteins will dominate, leading to high non-specific binding, compromising image contrast. It has 
been demonstrated for radiotracers crossing the blood-brain barrier that a Log Po/w range of 1.5 – 3 is 
optimal.56 While this range works equally well for non-brain receptor-targeted tracers, estrogen 
radioprobes with higher lipophilicity (up to Log P = 4.5) have been successful tumor imaging agents.57 
Therefore, the Log Po/w range for the selection of the EGFR probes in the current study has been set from 
1.5 to 4. The HPLC derived lipophilicities (Log Po/w) ranged from 2.2 to 5.5. Of those compounds 
previously chosen, 10a and 11b-d and 16a fall within this desired range. 
Selectivity for the chosen receptor is the final in vitro test. One preliminary measure of receptor 
selectivity that was employed in this study was to evaluate ErbB2 and ErbB4 inhibition. All of the 
compounds were much less potent inhibitors of ligand-induced ErbB2 and ErbB4 phosphorylation than 
of ligand-induced EGFR phosphorylation. Indeed the compounds tested here exhibit between one and 
two orders of magnitude of selectivity for the EGFR over ErbB2 or ErbB4. All of the compounds tested 
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 may be reasonable EGFR-selective tumor imaging agents. The optimal agent would exhibit the least 
amount of avidity for other RTKs. In many types of tumor cells ErbB2 is frequently overexpressed at 
levels comparable to the levels of EGFR overexpression.7 Similarly, ErbB4 is expressed in the normal 
mammary epithelium59 and infrequently overexpressed in tumor tissue.58, 59 These observations 
highlight the need for EGFR-selective imaging agents that exhibit minimal binding to ErbB2 and ErbB4, 
among other RTKs, in order to determine and understand EGFR expression using molecular imaging 
techniques.  
The quinazoline compounds were also assayed for inhibition of cellular DNA synthesis in EGF-
dependent (MCF10A) and EGF-independent (MCF7) cell lines.  This assay, like the inhibition of 
ligand-induced receptor tyrosine phosphorylation assays, not only assesses the specificity of a 
compound for EGFR, but also provides a measure of a compounds ability to penetrate cells and 
specifically target the EGFR.  Thus, it is not surprising that compound 12, which we hypothesized failed 
to inhibit ligand-induced EGFR tyrosine phosphorylation because it exhibits limited cell penetration, 
also failed to inhibit EGF-dependent and –independent DNA synthesis.  
In general, the MCF10A DNA synthesis IC50 values are much lower than the MCF7 DNA 
synthesis IC50 values.   This suggests that the compounds inhibit DNA synthesis in the MCF10A cells 
by primarily targeting EGFR.  Indeed, this assay has been used to connote that Lavendustin A analogs, 
which inhibit EGFR kinase activity, inhibit cell proliferation by inhibiting tubulin polymerization.50 
This indicates that at least some of the compounds inhibit DNA synthesis in the MCF7 cells by targeting 
a protein other than the EGFR.  Compounds that may target ATPases other than the EGFR would be 
expected to exhibit reduced MCF7/MCF10A DNA synthesis IC50 ratios.  Compounds with reduced 
ratios include 11d, 13, and 17b.  Such molecules may not be specific for the EGFR and may not be 
appropriate for further investigation as potential EGFR-specific tumor imaging agents. Compounds 10a-
d, 11b,c, 14, 16a,b and 17a exhibit elevated MCF7/MCF10A DNA synthesis IC50 ratios and by this 
criterion may be suitable for further investigation as a potential EGFR-specific tumor imaging agents. 
These criteria taken together support the further investigation of compounds 10a, 11b, 11c and 
16a. Compounds 10a, 4-(3´-fluoroanilino)- and 16a, 4-(2´-fluoroanilino)-6,7-diethoxyquinazoline, may 
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 both be labeled with the 110 min half-life fluorine-18. Compound 11b, 4-(3´-chloroanilino)-6,7-
dimethoxyquinazoline may be labeled with the 20 min half-life carbon-11; however, as pointed out 
earlier, the short half-life may not afford the time necessary to achieve the desired imaging 
pharmacokinetics. Compound 11c 4-(3´-bromoaniline)-6,7-dimethoxyquinaxoline may be a candidate 
for bromine-76 (16.2h positron emitter) labeling. 
Interestingly, Bonasera et al.38, have recently labeled three of the analogs studied in this paper, 
11a, 13 and 17b, and injected one of them, 17b, into A431 tumor-bearing mice. Compound 13 was not 
studied in vivo due to low measured EGFR inhibition values and compound 11a was not readily labeled 
with fluorine-18. Tumor uptake of [18F]17b at 30 minutes  was greater than 1% of the injected dose per 
gram (%ID/g) of tissue but the tumor to blood ratio was only 0.6. At 60 minutes the tumor uptake rose 
slightly to 1.34 %ID/g with a tumor to blood ratio of 1.62. This uptake may be associated with EGFR 
targeting but receptor blocking studies were not performed to demonstrate receptor mediated uptake. 
Bone uptake, an indicator of metabolic defluorination, was also not assessed. A second fluorine-labeled 
analog, 4-(3´, 4´- dichloro-6´-fluoroanilino)-6,7-dimethoxyquinazoline, was tested in tumor-bearing 
mice. Tumor accumulation of the probe never exceeded blood levels and the uptake was not receptor-
mediated. Several factors may have contributed to the limited tumor accumulation in vivo including high 
non-specific binding or diminished availability due to untoward metabolism. 
 It is clear from the preliminary studies that development of an effective EGFR imaging probe 
may present some challenges. Thus, effective screening of candidate probes and establishment of 
baseline data is essential for a radiopharmaceutical development program targeting EGFR.  
Conclusion 
Anilino-dialkoxyquinazolines suitable for labeling with radioisotopes were readily prepared 
using an approach amenable to a synthetic library of amino-quinazoline analogs. All of the dialkoxy 
analogs possessed suitable affinity for the EGF receptor and all analogs were potent inhibitors of ligand-
induced EGFR phosphorylation. They exhibited a range of lipophilicities based on the A ring and C ring 
substituents. Selectivity, as determined by comparison of ErbB2 and ErbB4 receptor inhibition to EGFR 
inhibition, favored the EGFR by 1-2 orders of magnitude. Based on measures of affinity, lipophilicity 
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 and selectivity, analogs 10a, 11b, 11c and 16a, were selected for further evaluation as tumor imaging 
probes. 
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 Experimental Section   
Chemistry.  Unless otherwise noted, all solvents and reagents were obtained from commercial 
suppliers (Aldrich Chemical, Co., Lancaster Synthesis, Inc., VWR, etc.) and were used without further 
purification. Melting points were determined using a Mel-Temp melting point apparatus and are 
reported uncorrected.  NMR spectra were recorded on either a Bruker VBAMX 300 300 MHz or AMX 
400 400 MHz.  Chemical shifts are reported in ppm (δ) relative to an internal standard.  Elemental 
analyses were performed by the Microanalytical Laboratory in the College of Chemistry, University of 
California, Berkeley. Mass spectral data was obtained on a Perkin Elmer SCIEX mass spectrometer at 
the SynPep Corporation facility (Dublin, CA) or on a VG ProSpec mass spectrometer at the Mass 
Spectrometry Facility in the College of Chemistry, University of California, Berkeley. 
 
2-nitro-4,5-diethoxybenzoic acid (2).   A flask immersed in a room-temperature water bath was 
charged with 3,4-diethoxybenzoic acid 1 (12.9 g, 61.4 mmol) and acetic acid (glacial, 52 mL).  Over a 
15 min. period HNO3 (70%, 54 mL) was added dropwise with stirring.  The deep orange solution was 
stirred for an additional 125 min. at room temperature.  The reaction was quenched upon addition of 110 
g of ice.  A yellow precipitate formed, which was filtered and washed with H2O (3 x 50 mL).  The 
resulting yellow-white solid was dissolved in ether (150 mL).  The ether was washed with 1N NaOH  (3 
x 60 mL).  The aqueous washings were combined, and acidified with concentrated HCl resulting in the 
production of a pale yellow precipitate.  The precipitate was filtered, washed with H2O (3 x 100 mL) 
and dissolved in  ether.  The ether was dried over MgSO4, and concentrated in vacuo to yield 10.55g 
(67%) of 2. mp 142-145 ˚C; 1H-NMR (CDCl3):  δ 7.36 (s, 1H, H-6), 7.21 (s, 1H, H-3), 4.20 (q, 2H, 
CH2CH3, J = 6.9 Hz), 4.17 (q, 2H, CH2CH3, J = 6.9 Hz), 1.50 (t, 6H, CH2CH3, J = 7.1 Hz). EI MS [M+]  
255 (100). 
2-amino-4,5-diethoxybenzoic acid (4).  a) A round-bottom flask containing 2-amino-4,5-diethoxy-
methyl benzoate 3 (1.00 g, 4.19 mmol, Sigma-Aldrich Rare Chemicals) was mixed with 6.25N NaOH 
(2.67 mL, 16.7 mmol) and water (5.0 mL).  The solution was refluxed for one hour to give a clear brown 
 16 
 solution.  After cooling at ambient temperature for 10 minutes, water (15 mL) was added to the flask 
and the solution was titrated to pH 6 with 1N HCl.   The solution was further cooled in an ice bath for 30 
minutes.  The precipitate was filtered, washed with water (100 mL) and pentanes (50 mL) and dried in 
vacuo over P2O5 overnight to give 0.83 g (76%) of 2-amino-4,5-diethoxybenzoic acid as a pale yellow 
solid. 
b)  An oven-dried round-bottomed flask (250 mL) equipped with a stirring bar was immersed in a room-
temperature water bath and charged with SnCl2•2H2O (24.9 g, 110 mmol) and HCl (conc., 100 mL).  2-
Nitro-4,5-diethoxybenzoic acid 2 (1.64 g, 6.43 mmol) was added and the mixture was stirred for 120 
min. at room temperature.  The mixture was diluted with HCl (conc., 40 mL), filtered, and washed with 
conc. HCl .  The resulting white solid was taken up in H2O (500 mL) and filtered to remove the 
remaining undissolved material.  The pH of the filtrate was adjusted to 4.5 using NH4OH.  The deep 
purple solution was extracted with CH2Cl2 (3 x 300 mL).  The organic washings were combined, dried 
over MgSO4, and concentrated in vacuo, to yield 0.64 g (44%) of a purple-white powder.  
mp 120-126 ˚C; 1H NMR (CDCl3):  δ 7.37 (s, 1H, H-6), 6.11 (s, 1H, H-3), 4.06 (q, 2H, CH2CH3, J = 6.8 
Hz), 4.01 (q, 2H, CH2CH3, J = 6.8 Hz), 1.46 (t, 3H, CH2CH3, J = 6.8 Hz), 1.41 (t, 3H, CH2CH3, J = 6.8 
Hz). EI MS [M+] 225 (100). 
 
6,7-diethoxyquinazolin-4-one (6). A modified literature procedure33 was developed to produce 6.  A 
500 mL round bottom flask equipped with an air condenser was charged with 2-amino-4,5-
diethoxybenzoic acid 4 (1.36 g, 6.04 mmol) and formamidine hydrochloride (0.70 g, 8.76 mmol).  The 
solids were thoroughly mixed then heated to 200 ˚C under an argon atmosphere for 15 minutes. The 
heating block temperature was adjusted to 80 ˚C and the solution cooled to 80 ˚C over 40 minutes.  
Dilute NaOH (0.33N, 20 mL) was added to the flask. The mixture was sonicated at room temperature 
for 1 hour producing in a dark gray-purple suspension.  The solid was filtered, washed with water (200 
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 mL), pentanes (200 mL), and ethyl acetate (200 mL) to give 6,7-diethoxy-quinazolin-4-one as an off-
white solid. Drying in vacuo overnight over P2O5 gave 0.80 g (57%) of 6. mp 248-251.5 ˚C;  1H-NMR 
(CD3OD): δ 7.98 (s, 1H, ArH), 7.55 (s, 1H, ArH), 7.11 (s, 1H, ArH), 4.20 (q, 2H, CH2CH3, J = 6.8 Hz), 
4.16 (q, 2H, CH2CH3, J = 6.8 Hz), 1.48 (t, 3H, CH2CH3, J = 6.8 Hz), 1.46 (t, 3H, CH2CH3, J = 6.8 Hz). 
EI MS [M+] 234 (100). 
 
6,7-dimethoxyquinazolin-4-one (7).  2-amino-4,5-dimethoxybenzoic acid 5 (5.0 g, 25.3 mmol) was 
converted to 7 in 65% yield (3.64 g) following the procedure for compound 6.  mp 278-278.5 ˚C; (lit.33 
mp 295-298 ˚C)  1H-NMR [(CD3)2SO]: δ 12.07 (br s, 1H, NH), 7.98 (s, 1H, ArH), 7.43 (s, 1H, ArH), 
7.11 (s, 1H, ArH), 3.90 (s, 3H, OCH3), 3.87 (s, 3H, OCH3). 
 
4-chloro-6,7-diethoxyquinazoline (8).   Following a modified literature procedure33, DMF (0.94 mL, 
12.1 mmol) was added dropwise to a solution of 1,2-dichloroethane (8.1 mL) and oxalyl chloride (1.1 
mL, 12.6 mmol) stirring under argon, vigorously releasing gas.  Following cessation of the gas 
production, 6,7-diethoxyquinazolin-4-one 6 (1.89 g, 8.1 mmol) was added to the thick white slurry then 
refluxed for 2.5 hours, resulting in a yellow-brown suspension.  The reaction was quenched by addition 
of Na2HPO4 (0.5M, 16.8 mL) followed by stirring in an ice bath for 1 hour.  The suspension was filtered 
and washed with water (200 mL) to isolate 4-chloro-6,7-diethyoxyquinazoline 8 as a pale gray solid, 
1.48 g (73%).  mp 139-140 ˚C;   1H-NMR (CDCl3): δ 8.82 (s, 1H, ArH), 7.35 (s, 1H, ArH), 7.28 (s, 1H, 
ArH), 4.26 (m, 4H, OCH2CH3), 1.55 (m, 6H, OCH2CH3). APCI MS [M+1] 253.1 (100), 255.1 (33).  
Anal. (C12H13ClN2O2) C,H,N. 
 
4-chloro-6,7-dimethoxyquinazoline (9).  6,7-dimethoxyquinazolin-4-one 7 (3.40 g, 16.5 mmol) was 
converted to 9 in 52% yield (1.91 g) following the procedure for compound 8.  mp 184-186 ˚C;   1H-
NMR (CDCl3): δ 8.86 (s, 1H, ArH), 7.38 (s, 1H, ArH), 7.32 (s, 1H, ArH), 4.05 (s, 6H, OCH3). APCI 
MS [M+1] 225.1 (100), 227.1 (30).  Anal. (C10H9ClN2O2) C,H,N. 
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 4-(3´-chloroanilino)-6,7-diethoxyquinazoline hydrochloride (10b): General coupling procedure.  A 
solution of 4-chloro-6,7-diethoxyquinazoline 8 (71 mg, 0.32 mmol) and 3-chloroaniline (40 μL, 0.38 
mmol) in 3 mL of DMF was heated at 80 ˚C under argon for 40 min.  The reaction was cooled at room 
temperature for 1 hour.  Ethyl acetate (2 mL) was added. The resulting precipitate was filtered and 
further washed with 20 mL of ethyl acetate to give the HCl salt 10a, 100 mg (90%).  The salt was 
converted to the free base by dissolving 10b in a mixture of 3 mL of ethyl acetate and 3 mL of 1N 
NaOH.  The biphasic mixture was stirred vigorously for several minutes.  The ethyl acetate layer was 
filtered, washed with water (3 x 1mL) and dried over MgSO4.  The ethyl acetate was filtered and the 
volume was reduced to less than 1 mL.  The solution was applied to a normal phase semi-preparative 
HPLC (Whatman M9/50 partisil 10 column, 70:30 EtOAc: hexane, 6 mL/min., UV 254 nm) for 
purification.  The fraction containing the free base was concentrated to dryness and the residue was 
dissolved in MeOH (8 mL) with gentle heating.  HCl (1N, 3 mL) was added and the solution was placed 
in an ice bath.  The precipitate was filtered and washed with ethyl acetate to give 72 mg (65%) of the 4-
(3-chloroanilino)-6,7-diethyoxyquinazoline hydrochloride salt 10b.  mp 260-261 ˚C; 1H NMR (CD3OD) 
δ 8.72 (s, 1H, H-2), 7.97 (s, 1H, Ar-H), 7.87 (s, 1H, H-2'), 7.65 (d, 1H, H-4', J = 8.0 Hz), 7.47 (t, 1H, H-
5' J = 8.1 Hz), 7.35 (d, 1H, H-6', J = 8.0 Hz), 7.20 (s, 1H, Ar-H), 4.31 (q, 4H, OCH2CH3, J = 6.9 Hz), 
1.55 (t, 6H, OCH2CH3, J = 7.0 Hz). EI MS [M+] 343 (100), 345 (34). Anal. (C18H18ClN3O2) C,H,N. 
 
4-(3´-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride (10a).  Similar treatment of 8 (0.021g, 
0.083 mmol) with 3-fluoroaniline yielded 10a (77%).mp 247.0-248.0 °C; 1H-NMR (CD3OD): δ 8.73 (s, 
1H, H-2), 7.99 (s, 1H, H-5), 7.66 (d, J=10.6 Hz, 1H, H-2'), 7.53 (m, 1H, H-5'), 7.53 (m, 1H, H-6'), 7.21 
(s, 1H, H-8), 7.08 (dd, J=9.1, 7.1 Hz, 1H, H-4'), 4.33 (q, J=6.9 Hz, 4H, CH3CH2O), 1.55 (t, J=6.9 Hz, 
3H, CH3CH2O), 1.54 (t, J=6.9 Hz, 3H, CH3CH2O).  EI MS [M] 327.  Anal. (C18H18FN3O2•HCl) C,H,N. 
 
4-(3´-bromoanilino)-6,7-diethoxyquinazoline hydrochloride (10c). Similar treatment of 8 (59.5 mg, 
0.24 mmol) with 3-bromoaniline yielded 10c (50%) mp 250-252 ˚C (Lit.33 mp 155-167 ˚C– free base).  
1H NMR [(CD3)2SO] δ 11.17 (br s, 1H, NH), 8.86 (s, 1H, H-2), 8.19 (s, 1H, Ar-H), 7.99 (s, 1H, H-2'), 
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 7.73 (d, 1H, H-4', J = 7.6 Hz), 7.51 (d, 1H, H-6', J = 7.5 Hz), 7.45 (t, 1H, H-5' J = 8.0 Hz), 7.23 (s, 1H, 
Ar-H), 4.27 (m, 4H, OCH2CH3, J = 7.2 Hz), 1.45 (t, 6H, OCH2CH3, J = 6.8 Hz).  HREIMS Calc for 
C18H18BrN3O2 m/z (M+) 387.05824, 389.05619 found  387.05776 , 389.05532  Anal. (C18H18BrN3O2) 
C,H,N. 
 
4-(3´-iodoanilino)-6,7-diethoxyquinazoline hydrochloride (10d).  Similar treatment of 8 (116.1 mg, 
0.46 mmol) with 3-iodoaniline yielded 10d (95%). mp 258.5-261 ˚C; 1H NMR [(CD3)2SO] δ 11.19 (br 
s, 1H, NH), 8.86 (s, 1H, H-2), 8.19 (s, 1H, Ar-H), 8.10 (s, 1H, H-2'), 7.75 (d, 1H, H-4', J = 8.0 Hz), 7.67 
(d, 1H, H-6', J = 8.0 Hz), 7.30 (s, 1H, Ar-H), 7.29 (t, 1H, H-5' J = 8.0 Hz), 4.27 (m, 4H, OCH2CH3), 
1.44 (t, 6H, OCH2CH3, J = 6.8 Hz).  APCI MS [M+1] 436.0 (100).  Anal. (C18H18IN3O2•HCl) C,H,N. 
 
4-(3´-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride (11a).  Similar treatment of 9 (0.032g, 
0.14 mmol) with 3-fluoroaniline yielded 11a (27%). mp 244.5-246.0 °C (Lit.33 mp 253-254 ˚C); 1H-
NMR (CD3OD): δ 8.72 (s, 1H, H-2), 7.82 (s, 1H, H-5), 7.47 (d, J=10.6 Hz, 1H, H-2'), 7.33 (m, 1H, H-
5'), 7.33 (m, 1H, H-6'), 7.03 (s, 1H, H-8), 6.89 (dd, J=8.6, 7.3 Hz, 1H, H-4'), 3.88 (s, 6H, CH3O).  EI MS 
[M] 299.  Anal. (C16H14FN3O2•1.1HCl) C,H,N. 
 
4-(3´-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride (11b).  Similar treatment of 9 (71.1 
mg, 0.32 mmol) with 3-chloroaniline yielded 11b (90%), mp 230-235 ˚C, (Lit.33 mp 261-262 ˚C); 1H 
NMR (CD3OD) δ 8.66 (s, 1H, H-2), 7.93 (s, 1H, Ar-H), 7.90 (s, 1H, H-2'), 7.66 (d, 1H, H-4', J = 8.0 
Hz), 7.44 (t, 1H, H-5' J = 8.1 Hz), 7.29 (d, 1H, H-6', J = 8.0 Hz), 7.21 (s, 1H, Ar-H), 4.02 (s, 6H, 
OCH3). HREIMS Calc for C16H14ClN3O2 m/z (M+) 315.07745, 317.07450 found 315.07682 , 
317.07303.  Anal. (C16H14ClN3O2•HCl) C,H,N. 
 
4-(3´-bromoanilino)-6,7-dimethoxyquinazoline hydrochloride (11c).  Similar treatment of 9 (312 mg, 
1.39 mmol) with 3-bromoaniline yielded 11c (87%). mp 256-257.5 ˚C; 1H NMR [(CD3)2SO] δ 11.35 (br 
s, 1H, NH), 8.88 (s, 1H, H-2), 8.29 (s, 1H, Ar-H), 8.01 (s, 1H, H-2'), 7.77 (d, 1H, H-4', J = 8.0 Hz), 7.50 
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 (d, 1H, H-6', J = 8.0 Hz), 7.45 (t, 1H, H-5' J = 8.0 Hz), 7.32 (s, 1H, Ar-H), 4.00 (s, 3H, OCH3), 3.99 (s, 
3H, OCH3).  EI MS [M+] 359 (100), 361 (97).  Anal. (C16H14BrN3O2•HCl) C,H,N. 
 
4-(3´-iodoanilino)-6,7-dimethoxyquinazoline hydrochloride (11d).  Similar treatment of 9 (276 mg, 
1.23 mmol) with 3-iodoaniline yielded 11d (92%).  mp 251-251.5 ˚C (Lit.33 mp 273 ˚C).  1H NMR 
[(CD3)2SO] δ 11.33 (br s, 1H, NH), 8.90 (s, 1H, H-2), 8.30 (s, 1H, Ar-H), 8.28 (s, 1H, H-2'), 7.79 (d, 
1H, H-4', J = 8.0 Hz), 7.69 (d, 1H, H-6', J = 8.0 Hz), 7.35 (s, 1H, Ar-H), 7.31 (t, 1H, H-5' J = 8.0 Hz), 
4.04 (s, 3H, OCH3), 4.02 (s, 3H, OCH3).  APCI MS [M+1] 408.0 (100).  Anal.  (C16H14IN3O2•HCl) 
C,H,N. 
 
4-(3´-fluoro-5´-trifluoromethylanilino)-6,7-diethoxyquinazoline hydrochloride (12).  Similar 
treatment of 8 (58.5 mg, 0.23 mmol) with 3-fluoro-5-trifluoromethylaniline yielded 12 (92%). mp 278-
280˚C; 1H NMR (CDCl3) δ 8.70 (s, 1H, H-2), 8.09 (d, 1H, H-4', JH,F = 10.9), 7.62 (s, 1H, Ar-H), 7.26 (s, 
1H, H-6'), 7.22 (br s, 1H, NH), 7.06 (d, 1H, H-2', JH,F = 8.0 Hz), 7.00 (s, 1H, Ar-H),  4.24 (m, 4H, 
OCH2CH3), 1.55 (m, 6H, OCH2CH3). HREIMS Calc for C19H17F4N3O2 m/z (M+) 395.12569 found 
395.12596. Anal. (C19H17F4N3O2•HCl) C,H,N. 
 
4-(3´-fluoro-5´-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride (13).  Similar 
treatment of 9 (150 mg, 0.67 mmol) with 3-fluoro-5-trifluoromethylaniline yielded 13 (19%). mp 269-
270.5 ˚C; 1H NMR (CDCl3) δ 8.72 (s, 1H, H-2), 8.08 (d, 1H, H-4', JH,F = 10.8), 7.63 (s, 1H, Ar-H), 7.38 
(br s, 1H, NH), 7.27 (s, 1H, H-6'), 7.06 (d, 1H, H-2', JH,F = 8.4 Hz), 7.02 (s, 1H, Ar-H),  4.03 (s, 3H, 
OCH3), 4.01 (s, 3H, OCH3).  APCI MS [M+1] 368.1 (100).   Anal.  (C17H13F4N3O2•HCl) C,H,N. 
 
4-[(4´-fluorobenzyl)amino]-6,7-diethoxyquinazoline hydrochloride (14).  Similar treatment of 8 
(66.9 mg, 0.26 mmol) with 4-fluorobenzylamine yielded 14 (84%). mp 238.5-240 ˚C; 1H NMR (CDCl3) 
δ 8.56 (s, 1H, H-2), 7.37 (dd, 2H, H-2',H-6',  JH,H = 8.2, JH,F = 5.5), 7.18 (s, 1H, Ar-H), 7.03 (t, 2H, H-3', 
H-5', JH,F = JH,F = 8.6 Hz), 6.84 (s, 1H, Ar-H), 5.53 (br s, 1H, NH), 4.81 (d, 2H, -CH2-, J = 5.4),  4.20 (q, 
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 2H, OCH2CH3, J = 7.0 Hz ), 4.12 (q, 2H, OCH2CH3, J = 7.0 Hz), 1.51 (t, 3H, OCH2CH3, J = 7.0 Hz), 
1.49 (t, 3H, OCH2CH3, J = 7.0 Hz).  EI MS [M+1] 341 (100). Anal. (C19H20FN3O2) C,H,N. 
 
4-[(4´-fluorobenzyl)amino]-6,7-dimethoxyquinazoline hydrochloride (15).  Similar treatment of 9 
(320 mg, 0.1.43 mmol) with 4-fluorobenzylamine yielded 15 (22%). mp 250-251 ˚C; 1H NMR  
[(CD3)2SO] δ 10.37 (br s, 1H, NH), 8.82 (s, 1H, H-2), 8.00 (s, 1H, Ar-H), 7.45 (dd, 2H, H-2',H-6',  JH,H 
= 8.4, JH,F = 5.6), 7.22 (s, 1H, Ar-H), 7.19 (t, 2H, H-3', H-5', JH,F = JH,F = 8.8 Hz),  4.91 (d, 2H, -CH2-, J 
= 5.2),  3.95 (s, 3H, OCH3), 3.94 (s, 3H, OCH3).  APCI MS [M+1] 314.2 (100).  Anal. 
(C17H16FN3O2•HCl) C,H,N. 
 
4-(2´-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride (16a).  Similar treatment of 8 (0.024g, 
0.095 mmol) 2-fluoroaniline yielded 16a (61%).  mp 220.5-222.0 °C; 1H-NMR (CD3OD): δ 8.62 (s, 1H, 
H-2), 7.91 (s, 1H, H-5), 7.57 (dd, J=7.7, 7.5 Hz, 1H, H-5'), 7.44 (m, 1H, H-4'), 7.32 (d, J=7.7 Hz, 1H, H-
6'), 7.28 (m, 1H, H-3'), 7.20 (s, 1H, H-8), 4.32 (q, J=6.6 Hz, 2H, CH3CH2O), 4.29 (q, J=6.6 Hz, 2H, 
CH3CH2O), 1.55 (t, J=6.6 Hz, 3H, CH3CH2O), 1.54 (t, J=6.6 Hz, 3H, CH3CH2O). HREIMS Calc for 
C18H18FN3O2 m/z (M+) 327.13831 found 327.13779. Anal. (C18H18FN3O2•1.4HCl) C,H,N.  
 
4-(4´-fluoroanilino)-6,7-diethoxyquinazoline hydrochloride (16b).  Similar treatment of 8 (0.10 g, 
0.40 mmol) with 4-fluoroaniline yielded 16b (97%). mp 252.0-255.0 °C; 1H-NMR ((CD3)2SO): δ 10.06 
(s, 1H, NH), 8.77 (d, J=1.8 Hz, 1H, H-2), 8.27 (s, 1H, H-5), 7.68 (m, 2H, H-2', H-6'), 7.32 (s, 1H, H-8), 
7.29 (dd, J=6.7, 6.6 Hz, 2H, H-3', H-5'), 4.25 (q, J=5.1 Hz, 2H, CH3CH2O), 4.20 (q, J=5.1 Hz, 2H, 
CH3CH2O), 1.41 (t, J=5.1 Hz, 3H, CH3CH2O), 1.40 (t, J=5.1 Hz, 3H, CH3CH2O). APCI MS [M+1] 
328.3.  Anal. (C18H18FN3O2•HCl) C,H,N. 
 
4-(2´-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride (17a).  Similar treatment of 9 (0.033g, 
0.15 mmol) with 2-fluoroaniline yielded 17a (50%).  mp 231.0-232.0 °C; 1H-NMR (CD3OD): δ 8.65 (s, 
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 1H, H-2), 7.97 (s, 1H, H-5), 7.58 (ddd, J=7.7, 7.5 Hz, 1.10 Hz, 1H, H-5'), 7.44 (m, 1H, H-4'), 7.33 (d, 
J=7.7 Hz, 1H, H-6'), 7.29 (m, 1H, H-3'), 7.25 (s, 1H, H-8), 4.09 (s, 3H, CH3O), 4.07 (s, 3H, CH3O). 
HREIMS Calc for C16H14FN3O2 m/z (M+) 299.10701 found 299.10648.  Anal. (C16H14FN3O2•HCl) 
C,H,N. 
 
4-(4´-fluoroanilino)-6,7-dimethoxyquinazoline hydrochloride (17b).  Similar treatment of 9 (0.10 g, 
0.45 mmol) with 4-fluoroaniline yielded 17b (94%).  mp 247.0-248.0 °C; 1H-NMR ((CD3)2SO): δ 10.12 
(br. s, 1H, NH), 8.79 (s, 1H, H-2), 8.25 (s, 1H, H-5), 7.68 (m, 2H, H-2', H-6'), 7.30 (dd, J=7.0, 6.2 Hz, 
2H, H-3', H-5'), 7.30 (s, 1H, H-8), 3.98 (s, 3H, CH3O), 3.96 (s, 3H, CH3O). APCI MS [M+1] 300.1.  
Anal. (C16H14FN3O2•HCl) C,H,N. 
 
Log P Determinations.  Log P values were estimated from the log k'w values determined by HPLC 
chromatography following the procedure of Minick.44 The solvents were HPLC grade methanol, 1-
octanol, n-decylamine and distilled deionized water.  The standards (p-anisidine [0.95]; acetophenone 
[1.58]; p-bromoaniline [2.26]; naphthalene [3.30]; pyrene [4.88]) were obtained from Aldrich and used 
without further purification.  A ThermoQuest HPLC system equipped with an autoinjector, pump, 
diode-array UV/Vis detector and an Es Industries MC8 column (4.6 x 150 mm, 5μ, 60Å) was used for 
these measurements. The organic mobile phase was methanol containing 0.25% v/v 1-octanol.  The 
aqueous mobile phase was octanol saturated water containing 0.02 M 3-morpholinopropanesulfonic acid 
(MOPS) buffer, 0.15% v/v n-decylamine, adjusted to pH 7.4.  The flow rate was set at 1 mL/min.The 
quinazolines and standards were dissolved in methanol to a final concentration of approximately 0.1 mg/ 
mL and 10 μL was injected onto the column.  The column void volume was estimated from the retention 
time of uracil, which was included as a non-retained internal reference standard with each injection.  
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 The log k'w was determined by linear extrapolation of the compound residence time (retention volume 
less void volume) versus the methanol concentration over a range of 60 to 85% methanol mobile phase. 
Biological Methods. 
Cell Lines and Cell Culture.  The CEM human T lymphocyte cell line engineered to express ErbB4 
(CEM/4) and its culture conditions have been described previously.51,52 Briefly, these cells were 
propagated in RPMI supplemented with 10% heat-inactivated fetal bovine serum and 300 μg/ml G418.  
The BaF3 mouse lymphoid cell lines engineered to express either EGFR (BaF3/EGFR) or ErbB2 and 
ErbB3 together (BaF3/2+3) and the culture conditions for these cell lines have been described earlier.53 
Briefly, these cells were propagated in RPMI supplemented with 10% fetal bovine serum, 300 μg/ml 
G418, and 10% medium conditioned by WeHI cells.  This conditioned medium serves as a source for 
Interleukin 3. 
MCF-10A human mammary epithelial cells and MCF-7, MDA-MB-231, and MDA-MB-453 
human mammary tumor cell lines were obtained from the American Type Culture Collection (ATCC).  
These lines were propagated according to ATCC recommendations. 
Inhibition of Receptor Tyrosine Phosphorylation. The assay for inhibition of ErbB family receptor 
tyrosine phosphorylation was adapted from a previously-described protocol.52,53 Briefly, 200 mL 
cultures of CEM/4, BaF3/EGFR, or BaF3/2+3 cells were grown to saturation density (~106 cells/mL) 
and were incubated for 24 hours at 37oC in serum-free medium to reduce basal levels of receptor 
tyrosine phosphorylation.  The cells were collected by centrifugation and resuspended in serum-free 
medium at a final concentration of ~107 cells/mL (~20 mL of cells).  Cells were transferred to 
microcentrifuge tubes in 1 mL aliquots and putative kinase inhibitors were added to the cells.  Each 
tyrosine kinase inhibitor was tested at 3-5 different concentrations.  The inhibitors were dissolved in 5 
μL DMSO; hence, cells treated with 5 μL DMSO were used as a solvent control.  Cells were incubated 
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 in the presence of inhibitor for 2 hours at 37oC, then were incubated on ice for 20 minutes.  Chilling the 
cells reduces the amount of ligand-induced receptor downregulation.53 
 Ligand was then added to the appropriate samples at a final concentration of 100 ng/mL and the 
samples were mixed and incubated on ice for 7 minutes.  Recombinant human Epidermal growth factor 
(EGF - Sigma) was used as the ligand for EGFR, whereas Neuregulin1β (NRG1β – R&D Systems) was 
used as the ligand for ErbB3 and ErbB4.  Note that because ErbB3 lacks kinase activity, ligand-induced 
ErbB2 and ErbB3 phosphorylation in the BaF3/2+3 cells is the result of ligand-induced ErbB2-ErbB3 
heterodimerization and ErbB2 kinase activity.53 Following incubation with ligand, the cells were 
collected by centrifugation, the supernatant was removed by aspiration, and the cells were resuspended 
in an isotonic lysis buffer containing 0.5% NP40/Igepal CA-630 (non-ionic detergent - Sigma).  
 The cells were incubated for 20 minutes on ice to permit lysis.  The samples were centrifuged for 
10 minutes at 4oC to collect the nuclei and cellular debris.  The supernatants (cell lysates) were 
transferred to fresh tubes.  Concanavalin A Sepharose (Amersham/Pharmacia) beads were added to each 
sample (35 μL of a 50% v/v slurry) and the samples were incubated at 4oC for 30 minutes.  
Concanavalin A Sepharose precipitates the cellular glycoproteins, which include ErbB family receptors.  
The precipitated glycoproteins were washed three times with 500 μL ice-cold lysis buffer, then were 
eluted by boiling the beads for five minutes in 80 μL reducing SDS protein sample buffer.  The beads 
were collected by centrifugation and half of the eluted glycoproteins (40 μL) were recovered and 
resolved by SDS/PAGE on a 7.5% acrylamide gel. 
 The resolved glycoproteins were electroblotted onto nitrocellulose (BiotraceNT – Gelman 
Sciences).  The resulting blot was blocked by incubation for 45 minutes at room temperature in a 
solution consisting of 5% bovine serum albumin (Sigma) dissolved in Tris-buffered normal saline (TBS) 
supplemented with 0.05% Tween-20 (TBS-T).  The blot was then probed with a mouse monoclonal 
antiphosphotyrosine antibody (4G10 – Upstate Biotechnology).  The blot was washed with TBS-T 5 
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 times for 6 minutes each, and primary antibody binding was detected by probing the blot with a goat 
anti-mouse antibody conjugated to horseradish perioxidase (HRP – Pierce).  The blot was washed with 
TBS-T 12 times for 10 minutes each, after which HRP activity was visualized by enhanced 
chemiluminescence (ECL – Amersham Pharmacia Biotech).  The resulting chemilumigrams were 
digitized using a Linotype-Hell Jade flatbed scanner and the amount of receptor tyrosine 
phosphorylation was quantified using NIH Image software.  The amount of receptor tyrosine 
phosphorylation in samples from cells treated with a putative receptor tyrosine kinase inhibitor were 
compared to a standard curve generated using samples from cells treated with DMSO solvent control.  
This enabled us to determine the concentration of a given tyrosine kinase inhibitor that was necessary to 
cause a 50% reduction in receptor tyrosine phosphorylation.  This value is reported as the receptor 
tyrosine phosphorylation IC50 value. 
 
Inhibition of Cellular DNA Synthesis. The assay for inhibition of cellular DNA synthesis was adapted 
from a previously-described protocol.54 Briefly, human mammary (tumor) cells were seeded in 1 mL 
aliquots into 24-well culture dishes at a density of 105 cells/well.  Cells were incubated for 24 hours at 
37oC, and a tyrosine kinase inhibitor dissolved in DMSO was added to each well in a volume of 10 μL.  
Each tyrosine kinase inhibitor was assayed at 3-5 different concentrations and each concentration was 
assayed using 3-4 wells of cells.  Cells treated with 10 μl DMSO served as the solvent control.  Cells 
were then incubated for 48 hours at 37oC.  3H-Thymidine (1.5 μCi – Amersham Pharmacia Biotech) 
dissolved in a 1.5 μL of an aqueous solution was added to each well and the cells were incubated for an 
additional 2 hours at 37oC.  The culture medium was aspirated from the wells, and the cells were rinsed 
once with 1 mL ice-cold phosphate-buffered saline (PBS) and once with 1 mL ice-cold 10% 
trichloroacetic acid (TCA).  Incorporated 3H-Thymidine was precipitated by incubating the cells for at 
least 30 minutes at 4oC in 1 mL 10% TCA.  Following incubation, the TCA solution was aspirated from 
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 each well and the precipitated (incorporated) 3H-Thymidine was solubilized by incubating the cells for 
30 minutes at 95oC in 500 μL 3% perchloric acid.  The perchloric acid extracts were transferred to 
scintillation vials containing 10 mL Cytoscint scintillation cocktail (ICN).  The incorporated 3H-
Thymidine was assayed by scintillation counting on a Packard Tricarb scintillation counter.  The amount 
of 3H-Thymidine incorporation observed in the cells treated with the solvent control was divided by 2 
(two) to determine the amount of 1/2 maximal 3H-Thymidine incorporation.  Dose response curves for 
each combination of putative tyrosine kinase inhibitor and cell line were then constructed using the 3H-
Thymidine incorporation data.  The dose response curves and the 1/2 maximal 3H-Thymidine values 
were used to calculate the concentration of each inhibitor required to inhibit 3H-Thymidine 
incorporation by 50% in a given cell line.  This value is reported as the DNA synthesis IC50 value. 
 
In Vitro EGFR Binding Assay.  EGFR tyrosine kinase receptor binding was determined by a 
competitive radiometric assay using [125I]-4-(3’- [125I]iodoanilino)-6,7-dimethoxyquinazoline36 as the 
radiotracer (Specific Activity = 590 Ci/mmol). Various concentrations  (10-11M – 10-6M) of the 
quinazoline compounds were prepared in binding buffer (10 mM HEPES, 1mM EDTA, 5 mM MgCl2, 
0.1%BSA, 10 μg/mL leupeptin, 10 μg/mL pepstatin, 0.5 μg/mL aprotin and 200 μg/mL bacitracin (pH 
7.4)). Commercially available (Receptor Biology, Beltsville, MD) A431 human carcinoma cell 
membrane were diluted in ice cold binding buffer (50 μL of 0.06 μg/μL stock solution)and 
homogenized with a hand held homogenizer. This preparation was added to the buffer solution followed 
by the addition of 1 μCi of the radiotracer to initiate the binding assay. The mixture was incubated at 
room temperature in the dark for 60 min. The incubation was terminated by the addition of 5 mL of ice 
cold buffer (10 mM HEPES, 1 mM EDTA, 5 mM MgCl2, and 0.1% BSA (pH 7.4)) and the solutions 
were filtered through polyethylenamine soaked (0.5% soln., 30 min) GF/B filter paper (Brandel, 
Gaithersburg, MD) using a Brandel Cell Harvester, followed by two washes (5 mL each) with wash 
buffer. The filter paper was dried and counted for 10 minutes using a TM Analytic gamma well counter.  
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 Non-specific binding was determined by adding 1 μM 4-(3′-bromoanilino)-dimethoxy quinazoline to the 
assay.  Inhibition constants at 50% of specific binding (IC50) were derived from specific binding versus 
concentration curves. Triplicate assays were performed for each compound. 
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 Table 1. 4-Anilino- and 4-Benzylamino- Quinazolines Chemical and Physical Data. 
 
HN
N
R1O
R1O N
R2
R3
HN
N
R1O
R1O N
R2
R3
HN
N
R1O
R1O N
R2
A B C  
 
no. type R1 R2 R3 mp (oC) formula anal. Log Po/wa
10a A CH3CH2 F H 247-248 C18H18FN3O2•HCl C,H,N 3.71 ± 0.12 
10b A CH3CH2 Cl H 260-261 C18H18ClN3O2•HCl C,H,N 4.31 ± 0.26 
10c A CH3CH2 Br H 250-252 C18H18BrN3O2 C,H,N 4.40 ± 0.25 
10d A CH3CH2 I H 258-261 C18H18IN3O2•HCl C,H,N 4.62 ± 0.26 
11a A CH3 F H 244.5-246 C16H14FN3O2•1.1HCl C,H,N 2.96 ± 0.10 
11b A CH3 Cl H 230-235 C16H14ClN3O2•HCl C,H,N 3.51 ± 0.23 
11c A CH3 Br H 256-257.5 C16H14BrN3O2•HCl C,H,N 3.49 ± 0.22 
11d A CH3 I H 251-251.5 C16H14IN3O2•HCl C,H,N 3.65 ± 0.22 
12 A CH3CH2 F CF3 278-280 C19H17F4N3O2•HCl C,H,N 5.49 ± 0.29 
13 A CH3 F CF3 269-270.5 C17H13F4N3O2•HCl C,H,N 4.66 ± 0.26 
14 B CH3CH2 F - 238.5-240 C19H20FN3O2 C,H,N 3.78 ± 0.23 
15 B CH3 F - 250-251 C17H16FN3O2•HCl C,H,N 3.02 ± 0.20 
16a C CH3CH2 F H 252-255 C18H18FN3O2•1.4HCl C,H,N 3.02 ± 0.11 
16b C CH3CH2 H F 220.5-222 C18H18FN3O2•HCl C,H,N 3.73 ± 0.23 
17a C CH3 F H 247-248 C16H14FN3O2•HCl C,H,N 2.20 ± 0.11 
17b C CH3 H F 231-232 C16H14FN3O2•HCl C,H,N 2.87 ± 0.21 
a Estimated by the reversed-phase HPLC method of Minick, et al.44 
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Table 2. Biochemical data for the EGFR tyrosine kinase (tk) inhibitors 
 Receptor Binding 
(IC50 nM) 
 Receptor  Phosphorylation 
(IC50 nM) 
 
no. EGFR tk EGFR tk ErbB2 tk ErbB4 tk 
10a 8.17 ± 1.57  6.5 ± 2.1   
10b 0.38 ± 0.13  1.2 ± 0.2   
10c 0.41 ± 0.09  3.2 ± 0.8  215 ± 87  50 ± 19 
10d 0.64 ± 0.15  4.6 ± 2.0  69 ± 10  59 ± 29 
11a 31.9 ± 7.00  6.3 ± 2.0   
11b 1.26 ± 0.00  0.8 ± 0.2   
11c 0.66 ± 0.12  2.6 ± 0.5  143 ± 52  49 ± 16 
11d 1.05 ± 0.51  6.4 ± 2.7   
12 8.95 ± 3.26 >50   
13 20.0 ± 10.2  19.1 ± 2.9   
14 17.0 ±   5.0  6.6 ± 1.6  231 ± 92 >100 
15 47.7 ± 14.1  10.9 ± 2.8   
16a 9.31 ± 1.19  15.8 ± 2.2   
16b 16.0 ±   3.7  23.1 ± 4.2   
17a 32.2 ±   7.4  12.8 ± 3.5   
17b 51.0 ± 11.7  19.1  ± 2.5   
 
Table 3.  Inhibition of DNA Synthesis  (IC50 nM) 
no. MCF-10Aa MCF-7b MCF-7/ MCF-10A 
10a 99   ± 16 1923 ± 456 19.5 
10b 108  ± 8 1087 ± 402 10.1 
10c 78   ± 12 1695 ± 169 21.7 
10d 153 ± 25 1571 ± 263 10.3 
11a 59   ±  5 1956 ± 842 33.2 
11b 173 ±  24 1982 ± 387 11.5 
11c 211 ± 45 1613 ± 123 7.6 
11d 585 ± 108 2433 ±   61 4.2 
12 >3000 N.D. -- 
13 1634 ± 100 4717 ± 1014 2.9 
14 188   ± 25 1433 ±   88 7.6 
15 489   ±  87 >7000  
16a 141   ± 17 1101 ± 656 7.8 
16b 622  ±  69 7487 ± 505 12.0 
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 17a 179   ± 31 1950 ± 260 10.9 
17b 612   ± 134 3375 ± 686 5.5 
a EGF-dependent human mammary epithelial cell line 
b EGF-independent human mammary tumor cell line 
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 Figure Captions: 
 
Figure 1. EGFR tyrosine kinase inhibitors13,16,34,55 
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(i) 70% HNO3/ glacial acetic acid/ 2 h/ RT; 
(ii) SnCl2/ HCl/ 2 h/ RT; (iii) NaOH/ 
reflux/1 h, then HCl 
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(i) formamidine•HCl/ heat then NaOH/ 
sonicate/ 1 h/ RT;  (ii) oxalyl chloride/ DMF/ 
1,2-dichloroethane/ reflux 
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(i) 3-haloaniline/ DMF/ heat; (ii) 3-fluoro-5-trifluoromethylaniline/ DMF/ heat; 
(iii) 4-fluorobenzylamine/ DMF/ heat.; (iv) 2- or 4-fluoroaniline/ DMF/ Heat 
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